Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Invested Capital (2016 - 2025)

Anaptysbio filings provide 10 years of Invested Capital readings, the most recent being $37.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 47.49% year-over-year to $37.2 million, compared with a TTM value of $37.2 million through Dec 2025, down 47.49%, and an annual FY2025 reading of $37.2 million, down 47.49% over the prior year.
  • Invested Capital hit $37.2 million in Q4 2025 for Anaptysbio, up from -$29.4 million in the prior quarter.
  • The five-year high for Invested Capital was $385.7 million in Q2 2021, with the low at -$44.7 million in Q2 2025.
  • Median Invested Capital over the past 5 years was $134.4 million (2023), compared with a mean of $172.0 million.
  • The sharpest move saw Invested Capital increased 6.49% in 2021, then tumbled 552.81% in 2025.
  • Year by year, Invested Capital stood at $356.4 million in 2021, then fell by 26.46% to $262.1 million in 2022, then crashed by 66.39% to $88.1 million in 2023, then decreased by 19.56% to $70.9 million in 2024, then tumbled by 47.49% to $37.2 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $37.2 million, -$29.4 million, and -$44.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.